DOP2023000095A - Composición farmacéutica sólida recubierta y estable de un analgésico opioide y un antiepiléptico para el dolor - Google Patents

Composición farmacéutica sólida recubierta y estable de un analgésico opioide y un antiepiléptico para el dolor

Info

Publication number
DOP2023000095A
DOP2023000095A DO2023000095A DO2023000095A DOP2023000095A DO P2023000095 A DOP2023000095 A DO P2023000095A DO 2023000095 A DO2023000095 A DO 2023000095A DO 2023000095 A DO2023000095 A DO 2023000095A DO P2023000095 A DOP2023000095 A DO P2023000095A
Authority
DO
Dominican Republic
Prior art keywords
pain
antiepileptic
coated
solid
pharmaceutical composition
Prior art date
Application number
DO2023000095A
Other languages
English (en)
Spanish (es)
Inventor
Alejandro González Canudas Jorge
Cuahutencos Escobar Ernesto
Yazmín Ollervides Rubio Paola
Jannette Muñoz Martinez Cecilia
Serafín Espinoza De León Sixto
Original Assignee
Laboratorios Silanes S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Silanes S A De C V filed Critical Laboratorios Silanes S A De C V
Publication of DOP2023000095A publication Critical patent/DOP2023000095A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DO2023000095A 2020-12-04 2023-05-12 Composición farmacéutica sólida recubierta y estable de un analgésico opioide y un antiepiléptico para el dolor DOP2023000095A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2020/050050 WO2022119430A1 (es) 2020-12-04 2020-12-04 Composición farmacéutica sólida recubierta y estable de un analgésico opioide y un antiepiléptico para el dolor

Publications (1)

Publication Number Publication Date
DOP2023000095A true DOP2023000095A (es) 2023-06-15

Family

ID=81853431

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2023000095A DOP2023000095A (es) 2020-12-04 2023-05-12 Composición farmacéutica sólida recubierta y estable de un analgésico opioide y un antiepiléptico para el dolor

Country Status (10)

Country Link
US (1) US20240000727A1 (https=)
EP (1) EP4230199A4 (https=)
JP (1) JP7720911B2 (https=)
KR (1) KR20230117591A (https=)
CA (1) CA3199166A1 (https=)
CO (1) CO2023008896A2 (https=)
DO (1) DOP2023000095A (https=)
MX (1) MX2022015331A (https=)
PE (2) PE20252763A1 (https=)
WO (1) WO2022119430A1 (https=)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637767A (en) 1995-06-07 1997-06-10 Warner-Lambert Company Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US20020187996A1 (en) 2001-05-14 2002-12-12 Dewey Stephen L. Prevention of addiction in pain management
KR20060108692A (ko) 2003-10-31 2006-10-18 알자 코포레이션 메트포르민의 개선된 흡수를 위한 조성물 및 제형
MX2007008833A (es) 2005-01-21 2008-03-25 Pharmanova Inc Formulaciones farmaceuticas y metodos de uso.
JP2007018123A (ja) 2005-07-06 2007-01-25 Kyocera Mita Corp 画像処理装置、及び画像処理システム
MXPA05011735A (es) 2005-11-01 2007-04-30 Leopoldo Espinosa Abdala Composiciones farmaceuticas que comprenden combinaciones de analgesicos y anticonvulsivantes para el tratamiento del dolor agudo y cronico.
DE102007019071A1 (de) 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
CL2008003800A1 (es) 2007-12-21 2010-01-22 Synthon Bv Sal de acido sulfonico de pregabalina, procedimiento de preparacion, composicion farmaceutica, util para tratar trastornos neuropsiquiatricos, esquizofrenia, epilepsia, fibromialgia, trastorno de ansiedad generalizada, trastorno de panico y fobia social y dolor por ejemplo dolor neuropatico.
TR200909613A1 (tr) 2009-12-22 2011-07-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Pregabalinin farmasötik bileşimleri.
AU2011276170B2 (en) 2010-07-06 2016-03-10 Grunenthal Gmbh Novel gastro- retentive dosage forms comprising a GABA Analog and an opioid
US20130189354A1 (en) 2010-10-07 2013-07-25 Trinity Laboratories, Inc., Novel Pharmaceutical Compositions for Treating Chronic Pain and Pain Associated with Neuropathy
US20150313892A1 (en) * 2014-02-07 2015-11-05 Trinity Laboratories, Inc. Pharmaceutical compositions for treating pain associated with dysmenorrhea
WO2018015946A1 (en) 2016-07-17 2018-01-25 Mapi Pharma Ltd. Extended release dosage forms of pregabalin
MX2017016720A (es) 2017-12-19 2019-06-20 Monte Verde S A Composición farmacéutica que contiene un analgésico de tipo opioide en combinación con un análogo del ácido g-aminobutírico (gaba).
KR20190075718A (ko) * 2017-12-21 2019-07-01 주식회사 네비팜 용출율이 개선된 트라마돌 또는 이의 약학적으로 허용가능한 염 및 프레가발린 또는 이의 약학적으로 허용가능한 염을 포함하는 다층 제제
WO2020044070A1 (es) * 2018-08-30 2020-03-05 Grünenthal GmbH Combinación farmacéutica sinérgica que comprende tramadol clorhidrato y pregabalina, y su uso para el tratamiento del dolor neuropático

Also Published As

Publication number Publication date
CA3199166A1 (en) 2022-06-09
MX2022015331A (es) 2023-02-01
PE20252750A1 (es) 2025-12-05
JP7720911B2 (ja) 2025-08-08
WO2022119430A1 (es) 2022-06-09
KR20230117591A (ko) 2023-08-08
JP2024504902A (ja) 2024-02-02
PE20252763A1 (es) 2025-12-22
EP4230199A1 (en) 2023-08-23
US20240000727A1 (en) 2024-01-04
EP4230199A4 (en) 2024-07-31
CO2023008896A2 (es) 2023-08-18

Similar Documents

Publication Publication Date Title
CA2750219C (en) Transdermal delivery of diclofenac, carbamazepine and benzydamine
JP2024028490A (ja) ロキソプロフェンを含有する医薬組成物＜陸＞
JP2023523155A5 (https=)
UY25234A1 (es) Formulación de liberación prolongada de venlafaxina
MX2019001596A (es) Uso y dosificacion de agentes terapeuticos para endometriosis.
BRPI0405221A (pt) Composição medicinal estável sólida para administração oral
EA202000165A1 (ru) ПРОТИВО-PHK ВИРУСНАЯ, В ТОМ ЧИСЛЕ ПРОТИВО-SARS-CoV-2 ВИРУСНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ АВИФАВИР
FI3706724T3 (fi) Suun kautta otettavia rifamysiini sv -koostumuksia
AR046410A1 (es) Composiciones farmaceuticas para la liberacion modificada de modafinilo
EA023535B9 (ru) Композиция водного радиопротекторного фармацевтического раствора и способ предотвращения, снижения или исключения эффектов ионизирующей радиации
CO2023008896A2 (es) Composición farmacéutica sólida recubierta y estable de un analgésico opioide y un antiepiléptico para el dolor
DOP2024000272A (es) Composición farmacéutica sinérgica y estable de un aine y un analgésico opioide para el dolor e inflamación
MA58327B2 (fr) Nouveau composé de [2-(diméthylamino)-2-phénylbutyl]-3,4,5-triméthoxybenzoate 4-méthyl-2н-chromen-2-one-7-ylsulfate et son utilisation
KR102194015B1 (ko) 정맥내 항바이러스 치료
ES2182504T3 (es) Bifenilsulfonilcianamidas, procedimiento para su preparacion y su utilizacion como medicamento.
ES2751746T3 (es) Formulaciones farmacéuticas sólidas estables que contienen 2-(2-nitro-4-trifluorometilbenzoil)-1,3-ciclohexanodiona
BRPI0710095A2 (pt) inibidores de renina para o tratamento de hipertensão
EP1180058A1 (en) Combinations of gaba analogs and tricyclic compounds to treat depression
PE20252741A1 (es) Formulaciones de dosis de una sola unidad de alta concentracion y metodos de uso de estas
Brinton Newer HMG‐CoA reductase inhibitor (statin) therapies
JOP20240162A1 (ar) تركيبة صيدلية تتضمن مشتق فثالازينون للإعطاء المشترك مع عقار مضاد للسرطان
EA201900293A3 (ru) Трансдермальный препарат для лечения и профилактики болезней суставов и мягких тканей
AR108008A1 (es) Unas dosis unitarias de liberación inmediata de ghb o una de sus sales terapéuticamente aceptables administradas por vía oral
HUP0103110A2 (hu) Transzdermálisan adagolható aszpirinkészítmény
AU2016262644A1 (en) Intravenous antiviral treatments